These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

148 related items for PubMed ID: 19519868

  • 1. Synergistic effect of the human GLP-1 analogue liraglutide and a dual PPARalpha/gamma agonist on glycaemic control in Zucker diabetic fatty rats.
    Brand CL, Galsgaard ED, Tornehave D, Rømer J, Gotfredsen CF, Wassermann K, Knudsen LB, Vølund A, Sturis J.
    Diabetes Obes Metab; 2009 Aug; 11(8):795-803. PubMed ID: 19519868
    [Abstract] [Full Text] [Related]

  • 2. Long-term liraglutide treatment is associated with increased insulin content and secretion in β-cells, and a loss of α-cells in ZDF rats.
    Schwasinger-Schmidt T, Robbins DC, Williams SJ, Novikova L, Stehno-Bittel L.
    Pharmacol Res; 2013 Oct; 76():58-66. PubMed ID: 23891763
    [Abstract] [Full Text] [Related]

  • 3. Combination of the insulin sensitizer, pioglitazone, and the long-acting GLP-1 human analog, liraglutide, exerts potent synergistic glucose-lowering efficacy in severely diabetic ZDF rats.
    Larsen PJ, Wulff EM, Gotfredsen CF, Brand CL, Sturis J, Vrang N, Knudsen LB, Lykkegaard K.
    Diabetes Obes Metab; 2008 Apr; 10(4):301-11. PubMed ID: 18333889
    [Abstract] [Full Text] [Related]

  • 4. TAK-875, a GPR40/FFAR1 agonist, in combination with metformin prevents progression of diabetes and β-cell dysfunction in Zucker diabetic fatty rats.
    Ito R, Tsujihata Y, Matsuda-Nagasumi K, Mori I, Negoro N, Takeuchi K.
    Br J Pharmacol; 2013 Oct; 170(3):568-80. PubMed ID: 23848179
    [Abstract] [Full Text] [Related]

  • 5. Neurturin and a GLP-1 Analogue Act Synergistically to Alleviate Diabetes in Zucker Diabetic Fatty Rats.
    Trevaskis JL, Sacramento CB, Jouihan H, Ali S, Le Lay J, Oldham S, Bhagroo N, Boland BB, Cann J, Chang Y, O'Day T, Howard V, Reers C, Winzell MS, Smith DM, Feigh M, Barkholt P, Schreiter K, Austen M, Andag U, Thompson S, Jermutus L, Coghlan MP, Grimsby J, Dohrmann C, Rhodes CJ, Rondinone CM, Sharma A.
    Diabetes; 2017 Jul; 66(7):2007-2018. PubMed ID: 28408435
    [Abstract] [Full Text] [Related]

  • 6. The effects of 13 wk of liraglutide treatment on endocrine and exocrine pancreas in male and female ZDF rats: a quantitative and qualitative analysis revealing no evidence of drug-induced pancreatitis.
    Vrang N, Jelsing J, Simonsen L, Jensen AE, Thorup I, Søeborg H, Knudsen LB.
    Am J Physiol Endocrinol Metab; 2012 Jul 15; 303(2):E253-64. PubMed ID: 22589391
    [Abstract] [Full Text] [Related]

  • 7. Dual PPARalpha /gamma activation provides enhanced improvement of insulin sensitivity and glycemic control in ZDF rats.
    Brand CL, Sturis J, Gotfredsen CF, Fleckner J, Fledelius C, Hansen BF, Andersen B, Ye JM, Sauerberg P, Wassermann K.
    Am J Physiol Endocrinol Metab; 2003 Apr 15; 284(4):E841-54. PubMed ID: 12475752
    [Abstract] [Full Text] [Related]

  • 8. The anti-diabetic effects of GLP-1-gastrin dual agonist ZP3022 in ZDF rats.
    Skarbaliene J, Secher T, Jelsing J, Ansarullah, Neerup TS, Billestrup N, Fosgerau K.
    Peptides; 2015 Jul 15; 69():47-55. PubMed ID: 25849341
    [Abstract] [Full Text] [Related]

  • 9. The dual PPARalpha/gamma agonist, ragaglitazar, improves insulin sensitivity and metabolic profile equally with pioglitazone in diabetic and dietary obese ZDF rats.
    Pickavance LC, Brand CL, Wassermann K, Wilding JP.
    Br J Pharmacol; 2005 Feb 15; 144(3):308-16. PubMed ID: 15655531
    [Abstract] [Full Text] [Related]

  • 10. Treatment with CNX-011-67, a novel GPR40 agonist, delays onset and progression of diabetes and improves beta cell preservation and function in male ZDF rats.
    Gowda N, Dandu A, Singh J, Biswas S, Raghav V, Lakshmi MN, Shilpa PC, Sunil V, Reddy A, Sadasivuni M, Aparna K, Verma MK, Moolemath Y, Anup MO, Venkataranganna MV, Somesh BP, Jagannath MR.
    BMC Pharmacol Toxicol; 2013 May 21; 14():28. PubMed ID: 23692921
    [Abstract] [Full Text] [Related]

  • 11. Liraglutide: the therapeutic promise from animal models.
    Knudsen LB.
    Int J Clin Pract Suppl; 2010 Oct 21; (167):4-11. PubMed ID: 20887299
    [Abstract] [Full Text] [Related]

  • 12. Oral salmon calcitonin attenuates hyperglycaemia and preserves pancreatic beta-cell area and function in Zucker diabetic fatty rats.
    Feigh M, Andreassen KV, Neutzsky-Wulff AV, Petersen ST, Hansen C, Bay-Jensen AC, Henriksen JE, Beck-Nielsen H, Christiansen C, Henriksen K, Karsdal MA.
    Br J Pharmacol; 2012 Sep 21; 167(1):151-63. PubMed ID: 22506938
    [Abstract] [Full Text] [Related]

  • 13. Design and methods of a randomised double-blind trial of adding liraglutide to control HbA1c in patients with type 2 diabetes with impaired glycaemic control treated with multiple daily insulin injections (MDI-Liraglutide trial).
    Lind M, Hirsch IB, Tuomilehto J, Dahlqvist S, Torffvit O, Pehrsson NG.
    Prim Care Diabetes; 2015 Feb 21; 9(1):15-22. PubMed ID: 25175385
    [Abstract] [Full Text] [Related]

  • 14. Positive effects of GLP-1 receptor activation with liraglutide on pancreatic islet morphology and metabolic control in C57BL/KsJ db/db mice with degenerative diabetes.
    Moffett RC, Patterson S, Irwin N, Flatt PR.
    Diabetes Metab Res Rev; 2015 Mar 21; 31(3):248-55. PubMed ID: 25256010
    [Abstract] [Full Text] [Related]

  • 15. GLP-1 derivative liraglutide in rats with beta-cell deficiencies: influence of metabolic state on beta-cell mass dynamics.
    Sturis J, Gotfredsen CF, Rømer J, Rolin B, Ribel U, Brand CL, Wilken M, Wassermann K, Deacon CF, Carr RD, Knudsen LB.
    Br J Pharmacol; 2003 Sep 21; 140(1):123-32. PubMed ID: 12967942
    [Abstract] [Full Text] [Related]

  • 16. Effects of the dual PPAR-α/γ agonist aleglitazar on glycaemic control and organ protection in the Zucker diabetic fatty rat.
    Bénardeau A, Verry P, Atzpodien EA, Funk JM, Meyer M, Mizrahi J, Winter M, Wright MB, Uhles S, Sebokova E.
    Diabetes Obes Metab; 2013 Feb 21; 15(2):164-74. PubMed ID: 22958363
    [Abstract] [Full Text] [Related]

  • 17. Taspoglutide, a novel human once-weekly analogue of glucagon-like peptide-1, improves glucose homeostasis and body weight in the Zucker diabetic fatty rat.
    Sebokova E, Bénardeau A, Sprecher U, Sewing S, Tobalina L, Migliorini C.
    Diabetes Obes Metab; 2010 Aug 21; 12(8):674-82. PubMed ID: 20590744
    [Abstract] [Full Text] [Related]

  • 18. Predictive factors of efficacy of combination therapy with basal insulin and liraglutide in type 2 diabetes when switched from longstanding basal-bolus insulin: Association between the responses of β- and α-cells to GLP-1 stimulation and the glycaemic control at 6 months after switching therapy.
    Horie I, Haraguchi A, Sako A, Akeshima J, Niri T, Shigeno R, Ito A, Nozaki A, Natsuda S, Akazawa S, Mori Y, Ando T, Kawakami A, Abiru N.
    Diabetes Res Clin Pract; 2018 Oct 21; 144():161-170. PubMed ID: 30194951
    [Abstract] [Full Text] [Related]

  • 19. Glucagon-like peptide-1 receptor agonist treatment reduces beta cell mass in normoglycaemic mice.
    Ellenbroek JH, Töns HA, Westerouen van Meeteren MJ, de Graaf N, Hanegraaf MA, Rabelink TJ, Carlotti F, de Koning EJ.
    Diabetologia; 2013 Sep 21; 56(9):1980-6. PubMed ID: 23771206
    [Abstract] [Full Text] [Related]

  • 20. Pharmacological characterization and antidiabetic activity of a long-acting glucagon-like peptide-1 analogue conjugated to an antithrombin III-binding pentasaccharide.
    Patterson S, de Kort M, Irwin N, Moffett RC, Dokter WH, Bos ES, Miltenburg AM, Flatt PR.
    Diabetes Obes Metab; 2015 Aug 21; 17(8):760-70. PubMed ID: 25929155
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.